Price
No data yet.
Social Signal Score
Company Profile
- Sector
- Financial Services
- Industry
- Asset Management
- Beta
- 0.95
- Country
- US
Quote
Valuation & Ratios
Returns & Efficiency
Valuation
SBIOhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
120+50.00%Social Signal Score
Mentions (6)
- Newsetftrends.com·7d ago·Positive
Biotech ETF SBIO Can Get Its Groove Back With rising Treasury yields and the Federal Reserve's recent interest rate hike ranking as the likely culprits, the previously hot ALPS Medical Breakthroughs ETF (SBIO) is in the midst of a correction. That pullback, though, may be a buying opportunity.
View source ↗ - Newsseekingalpha.com·11d ago·Negative
SBIO: Promising Pipelines, Insufficient Return Potential SBIO is rated Sell due to a significant overvaluation vs. its probability-weighted fair NAV of $37.86, far below the $62.22 market price. Current fund pricing capitalizes on large portions of future biotech success, exposing investors to downside if clinical or commercial outcomes disappoint. Despite credible late-stage pipelines and solid cash runways, dilution risk remains high, with modeled scenarios projecting negative annualized retur…
View source ↗ - Newsseekingalpha.com·13d ago·Negative
SBIO: Big Pharma Needs What This Fund Owns The ALPS Medical Breakthroughs ETF targets late-stage biotech firms primed for clinical catalysts and acquisition interest. SBIO's methodology requires at least one Phase II/III program and 24 months of cash, reducing dilution risk before key events. Recent acquisitions of top holdings post-August highlight SBIO's ability to capture M&A-driven upside and recycle capital into new prospects.
View source ↗ - Newsetftrends.com·20d ago·Neutral
SBIO ETF Rallies on Clinical Trial Wins & M&A Demand The biotechnology sector continues to ride a massive wave of medical innovation, and ETFs like the ALPS Medical Breakthroughs ETF (SBIO) appear to be capturing the upside. SBIO posted a solid 5% gain in August, fueled by positive clinical trial data and an accelerating pace of industry mergers and acquisitions.
View source ↗ - Newszacks.com·28d ago·Neutral
Should You Invest in the ALPS Medical Breakthroughs ETF (SBIO)? If you're interested in broad exposure to the Healthcare - Broad segment of the equity market, look no further than the ALPS Medical Breakthroughs ETF (SBIO), a passively managed exchange traded fund launched on December 31, 2014.
View source ↗ - Newsetftrends.com·49d ago·Negative
3 Small-Cap ETFs to Watch as Russell 2000 Hits Record The Russell 2000 closed at a new record high Friday amid continued upwards momentum for several market indexes. That index, with its focus on small-caps, could prove an intriguing source of investing opportunities, given the right approach.
View source ↗
Congress trades
- Thomas Richard Carpersenate · DE · disclosed May 1, 2023 (14d later)Sell$1,001 - $15,000
- Thomas Richard Carpersenate · DE · disclosed Mar 1, 2023 (14d later)Sell$1,001 - $15,000
- Thomas Richard Carpersenate · DE · disclosed Nov 3, 2022 (30d later)Sell$1,001 - $15,000
- Thomas Richard Carpersenate · DE · disclosed Apr 5, 2022 (29d later)Sell$1,001 - $15,000
- Thomas Richard Carpersenate · DE · disclosed Jan 4, 2022 (4d later)Sell$1,001 - $15,000
- Thomas Richard Carpersenate · DE · disclosed Dec 4, 2021 (5d later)Buy$1,001 - $15,000
- Thomas Richard Carpersenate · DE · disclosed May 17, 2021 (178d later)Buy$1,001 - $15,000
- Thomas Richard Carpersenate · DE · disclosed May 17, 2021 (410d later)Sell$1,001 - $15,000
- Thomas Richard Carpersenate · DE · disclosed Jan 7, 2021 (8d later)Buy$1,001 - $15,000
- Thomas Richard Carpersenate · DE · disclosed Dec 2, 2020 (12d later)Buy$1,001 - $15,000
- Thomas Richard Carpersenate · DE · disclosed May 4, 2020 (32d later)Sell$1,001 - $15,000
Self-reported filings, amounts as brackets. Via Senate/House disclosures.